Afamelanotide (Scenesse, Clinuvel Pharmaceuticals) is a linear MC1R selective tridecapeptide, approved by the FDA on October 8, 2019, and by the EMA on December 22, 2014, exclusively for the treatment of erythropoietic protoporphyria (EPP) in adults
This delivery method ensures your body absorbs the full potency of glutathione without degradation from digestion, unlike oral supplements
Shodiq PF, Ahmad Fe (2019) The ointment of peel dragon fruit ( Hylicereus costaricensis ) extract decreased the Interleukin-2 (IL-2) expression and the number of mononuclear inflammation cells toward open wound in skin of rats wistar
In October 2024, the group sued the agency over the removal of tirzepatide from the shortage list
It seems that the combination of both the orientation of HQ in the active site and the oxidative state of tyrosinase will define the behavior of HQ
This story is still unfolding